Literature DB >> 19122780

Decisional conflict among patients who accept or decline participation in phase I oncology studies.

Kathryn E Flynn1, Kevin P Weinfurt, Damon M Seils, Li Lin, Caroline B Burnett, Kevin A Schulman, Neal J Meropol.   

Abstract

WE COMPARED DECISIONAL CONFLICT among adults with advanced cancer who had accepted or declined participation in phase I cancer clinical trials. Respondents completed a 121-item questionnaire that included the Decisional Conflict Scale (DCS), which was designed to measure uncertainty in making health decisions. We used standardized effect sizes to compare the DCS scores of accepters (n = 250) and decliners (n = 65). Accepters had lower decisional conflict than decliners overall (d = 0.42; 95% confidence interval, 0.17--0.68) and on all subscales. Whether greater decisional conflict among decliners represents suboptimal decision-making and is reason for bioethical concern depends on how the results are interpreted. We offer three scenarios to explain the differences and describe opportunities for future empirical work.

Entities:  

Year:  2008        PMID: 19122780      PMCID: PMC2613310          DOI: 10.1525/jer.2008.3.3.69

Source DB:  PubMed          Journal:  J Empir Res Hum Res Ethics        ISSN: 1556-2646            Impact factor:   1.742


  17 in total

1.  The scales were highly correlated: P = 0.0001.

Authors:  Peter M Fayers
Journal:  Qual Life Res       Date:  2008-05-07       Impact factor: 4.147

2.  Randomized trial of a patient decision aid for choice of surgical treatment for breast cancer.

Authors:  V Goel; C A Sawka; E C Thiel; E H Gort; A M O'Connor
Journal:  Med Decis Making       Date:  2001 Jan-Feb       Impact factor: 2.583

3.  Validation of a decisional conflict scale.

Authors:  A M O'Connor
Journal:  Med Decis Making       Date:  1995 Jan-Mar       Impact factor: 2.583

4.  Intubation and mechanical ventilation for COPD: development of an instrument to elicit patient preferences.

Authors:  R E Dales; A O'Connor; P Hebert; K Sullivan; D McKim; H Llewellyn-Thomas
Journal:  Chest       Date:  1999-09       Impact factor: 9.410

5.  Patients' decision-making process regarding participation in phase I oncology research.

Authors:  Manish Agrawal; Christine Grady; Diane L Fairclough; Neal J Meropol; Kim Maynard; Ezekiel J Emanuel
Journal:  J Clin Oncol       Date:  2006-09-20       Impact factor: 44.544

Review 6.  Decision aids for patients facing health treatment or screening decisions: systematic review.

Authors:  A M O'Connor; A Rostom; V Fiset; J Tetroe; V Entwistle; H Llewellyn-Thomas; M Holmes-Rovner; M Barry; J Jones
Journal:  BMJ       Date:  1999-09-18

7.  Expectations of benefit in early-phase clinical trials: implications for assessing the adequacy of informed consent.

Authors:  Kevin P Weinfurt; Damon M Seils; Janice P Tzeng; Kate L Compton; Daniel P Sulmasy; Alan B Astrow; Nicholas A Solarino; Kevin A Schulman; Neal J Meropol
Journal:  Med Decis Making       Date:  2008-03-31       Impact factor: 2.583

8.  Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication.

Authors:  Neal J Meropol; Kevin P Weinfurt; Caroline B Burnett; Andrew Balshem; Al B Benson; Liana Castel; Sandra Corbett; Michael Diefenbach; Darrell Gaskin; Yun Li; Sharon Manne; John Marshall; Julia H Rowland; Elyse Slater; Daniel P Sulmasy; David Van Echo; Shakira Washington; Kevin A Schulman
Journal:  J Clin Oncol       Date:  2003-07-01       Impact factor: 44.544

9.  Patient expectations of benefit from phase I clinical trials: linguistic considerations in diagnosing a therapeutic misconception.

Authors:  K P Weinfurt; D P Sulmasy; K A Schulman; N J Meropol
Journal:  Theor Med Bioeth       Date:  2003

10.  Factors influencing hospital patients' preferences in the utilization of life-sustaining treatments.

Authors:  J Cohen-Mansfield; J A Droge; N Billig
Journal:  Gerontologist       Date:  1992-02
View more
  10 in total

1.  Enhancing decision making about participation in cancer clinical trials: development of a question prompt list.

Authors:  Richard F Brown; Elyse Shuk; Natasha Leighl; Phyllis Butow; Jamie Ostroff; Shawna Edgerson; Martin Tattersall
Journal:  Support Care Cancer       Date:  2010-07-01       Impact factor: 3.603

2.  Should pretest genetic counselling be required for patients pursuing genomic sequencing? Results from a survey of participants in a large genomic implementation study.

Authors:  Joel E Pacyna; Carmen Radecki Breitkopf; Sarah M Jenkins; Erica J Sutton; Caroline Horrow; Iftikhar J Kullo; Richard R Sharp
Journal:  J Med Genet       Date:  2018-12-22       Impact factor: 6.318

3.  Before Consent: Qualitative Analysis of Deliberations of Patients With Advanced Cancer About Early-Phase Clinical Trials.

Authors:  Sarah B Garrett; Thea M Matthews; Corey M Abramson; Christopher J Koenig; Fay J Hlubocky; Christopher K Daugherty; Pamela N Munster; Daniel Dohan
Journal:  JCO Oncol Pract       Date:  2019-10-11

Review 4.  Communication and informed consent in phase 1 trials: a review of the literature from January 2005 to July 2009.

Authors:  Valerie A Jenkins; John L Anderson; Lesley J Fallowfield
Journal:  Support Care Cancer       Date:  2010-03-04       Impact factor: 3.603

5.  A Model of Cancer Clinical Trial Decision-making Informed by African-American Cancer Patients.

Authors:  Jennifer A Wenzel; Olive Mbah; Jiayun Xu; Gyasi Moscou-Jackson; Haneefa Saleem; Kwame Sakyi; Jean G Ford
Journal:  J Racial Ethn Health Disparities       Date:  2015-06

6.  An evaluation of two decision-making scales for children with life-limiting illnesses.

Authors:  C Knapp; I C Huang; V Madden; S Vadaparampil; G Quinn; E Shenkman
Journal:  Palliat Med       Date:  2009-04-03       Impact factor: 4.762

7.  Non-financial conflicts of interest in academic grant evaluation: a qualitative study of multiple stakeholders in France.

Authors:  Hendy Abdoul; Christophe Perrey; Florence Tubach; Philippe Amiel; Isabelle Durand-Zaleski; Corinne Alberti
Journal:  PLoS One       Date:  2012-04-09       Impact factor: 3.240

8.  Core values of patients with advanced cancer considering participation in an early-phase clinical trial: a qualitative study.

Authors:  Jelle L P van Gurp; Liza G G van Lent; Nicole Stoel; Carin C D van der Rijt; Maja J A de Jonge; Saskia M Pulleman; Julia C M van Weert; Jeroen Hasselaar
Journal:  Support Care Cancer       Date:  2022-06-08       Impact factor: 3.359

9.  Realizing better doctor-patient dialogue about choices in palliative care and early phase clinical trial participation: towards an online value clarification tool (OnVaCT).

Authors:  Liza G G van Lent; Nicole K Stoel; Julia C M van Weert; Jelle van Gurp; Maja J A de Jonge; Martijn P Lolkema; Eelke H Gort; Saskia M Pulleman; Esther Oomen-de Hoop; Jeroen Hasselaar; Carin C D van der Rijt
Journal:  BMC Palliat Care       Date:  2019-11-29       Impact factor: 3.234

10.  Decisional Conflict after Deciding on Potential Participation in Early Phase Clinical Cancer Trials: Dependent on Global Health Status, Satisfaction with Communication, and Timing.

Authors:  Liza G G van Lent; Maja J A de Jonge; Mirte van der Ham; Marjolein van Mil; Eelke H Gort; Jeroen Hasselaar; Esther Oomen-de Hoop; Carin C D van der Rijt; Julia C M van Weert; Martijn P Lolkema
Journal:  Cancers (Basel)       Date:  2022-03-15       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.